Omada Health (OMDA, Financial) opened its first day of trading with a bang—jumping 21% to $23 after pricing its IPO at $19. That move gives the digital chronic-care startup a market cap of roughly $1.3 billion. The $150 million raise was more than just well received—investor demand came in more than 15x oversubscribed, with most allocations going to a concentrated group of institutional buyers. It's another sign that appetite for health-tech IPOs is heating up again. U.S. listings have raised nearly $25 billion year-to-date, and early-stage healthcare names are up an average of 18% since listing.
Founded in 2011, Omada offers virtual care between doctor visits—focused on diabetes, obesity, hypertension, and joint pain. What sets it apart? It's not chasing the GLP-1 gold rush. Instead, Omada supports people already on those drugs, helping them manage side effects, nutrition, and post-treatment maintenance. About 50,000 of its 679,000 members are on GLP-1s. CEO Sean Duffy told Bloomberg that while AI powers much of the back-end, real human interaction is what drives results. “Our members tell us they want a person—and I have yet to see anyone that feels accountable to ChatGPT,” he said.
Revenue for Q1 2025 came in just under $55 million—up from $35.1 million a year ago—while net losses narrowed by more than half to $9.4 million. That improving financial picture, combined with a clear niche in chronic care, could be what's drawing top-tier investors. Revelation Partners, Andreessen Horowitz, Fidelity, and USVP are all among the largest shareholders. The IPO was led by Morgan Stanley, Goldman Sachs, and JPMorgan. OMDA now trades on the Nasdaq Global Market—and it's one more sign that digital health might be staging a real comeback.
